GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ITOS stock, giving a Buy rating on November 12. Daina ...

Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and ...

GSK is a global biopharmaceutical company headquartered in Brentford ... durable protection and has a favorable efficacy and safety profile for up to three seasons. This essentially makes Arexvy ...

AnaptysBio has a past history of successes. There are 2 molecules in phase 2, but with no patient data. GSK news has hurt ANAB stock. Read more here.

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its ... his "Make America Healthy Again" agenda. Erica Kollmann GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions ...

Under his leadership, the North office was responsible for numerous global and Indian brands like, PepsiCo, Nestle, GSK ...

Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- ...

RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...

The safety and tolerability profile of gepotidacin in the ... areas or diseases with high unmet needs globally. GSK’s expertise and capabilities in innovation, access and stewardship position the ...